

Table 14.6
De Novo Posttransplant Solid Malignancy, 2000 to 2009
Kidney Recipients

	Year of Transplant									
	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009
Total # of Post-Tx Malignancies	1,278	1,239	1,133	1,138	1,115	999	894	583	381	189
Malignancies by Type										
Squamous/Basal Cell Carcinoma	660	640	587	588	575	468	476	302	203	109
Melanoma	41	31	35	35	32	25	35	21	18	5
Kaposi Sarcoma	10	8	2	5	8	6	5	2	7	-
Central Nervous System	12	12	11	7	6	11	10	3	1	3
Genito-Urinary (1)	185	174	182	169	171	174	123	97	52	28
Gastro-Intestinal (2)	87	80	68	69	80	73	68	44	30	9
Primary Hepatic Tumor	12	10	9	6	15	11	9	12	7	2
Metastatic Hepatic Tumor	13	23	16	15	13	16	11	6	3	2
Larynx/Bronchi/Lung	99	112	94	97	101	96	68	28	23	8
Breast/Thyroid	72	67	59	79	55	57	36	38	17	14
Leukemia	6	9	11	4	10	7	3	2	5	2
Sarcoma (3)	4	6	-	6	6	1	3	5	1	-
Other	62	57	47	43	40	44	40	21	12	6
Unknown	15	10	12	15	3	10	7	2	2	1
Malignancies by Type (%)										
Squamous/Basal Cell Carcinoma	51.6%	51.7%	51.8%	51.7%	51.6%	46.8%	53.2%	51.8%	53.3%	57.7%
Melanoma	3.2%	2.5%	3.1%	3.1%	2.9%	2.5%	3.9%	3.6%	4.7%	2.6%
Kaposi Sarcoma	0.8%	0.6%	0.2%	0.4%	0.7%	0.6%	0.6%	0.3%	1.8%	-
Central Nervous System	0.9%	1.0%	1.0%	0.6%	0.5%	1.1%	1.1%	0.5%	0.3%	1.6%
Genito-Urinary (1)	14.5%	14.0%	16.1%	14.9%	15.3%	17.4%	13.8%	16.6%	13.6%	14.8%
Gastro-Intestinal (2)	6.8%	6.5%	6.0%	6.1%	7.2%	7.3%	7.6%	7.5%	7.9%	4.8%
Primary Hepatic Tumor	0.9%	0.8%	0.8%	0.5%	1.3%	1.1%	1.0%	2.1%	1.8%	1.1%
Metastatic Hepatic Tumor	1.0%	1.9%	1.4%	1.3%	1.2%	1.6%	1.2%	1.0%	0.8%	1.1%
Larynx/Bronchi/Lung	7.7%	9.0%	8.3%	8.5%	9.1%	9.6%	7.6%	4.8%	6.0%	4.2%
Breast/Thyroid	5.6%	5.4%	5.2%	6.9%	4.9%	5.7%	4.0%	6.5%	4.5%	7.4%
Leukemia	0.5%	0.7%	1.0%	0.4%	0.9%	0.7%	0.3%	0.3%	1.3%	1.1%
Sarcoma (3)	0.3%	0.5%	-	0.5%	0.5%	0.1%	0.3%	0.9%	0.3%	-
Other	4.9%	4.6%	4.1%	3.8%	3.6%	4.4%	4.5%	3.6%	3.1%	3.2%
Unknown	1.2%	0.8%	1.1%	1.3%	0.3%	1.0%	0.8%	0.3%	0.5%	0.5%
Total # of Patients	846	841	800	808	794	741	667	447	309	162

Source: OPTN/SRTR Data as of October 1, 2010.

Notes:

(-) = None in category.

(1) Genito-Urinary: kidney, bladder, uterine cervix, uterine body, ovarian, vulva, testicular, prostate.

(2) Gastro-Intestinal: tongue, throat, esophagus, stomach, small intestine, colo-rectal, liver and biliary tract, pancreas.

(3) Sarcoma: fibrosarcoma, osteosarcoma, etc.

Recipient malignancy statistics are based on voluntary reporting to the OPTN.